Biogen (NASDAQ:BIIB) Price Target Cut to $213.00 by Analysts at Royal Bank Of Canada

Biogen (NASDAQ:BIIB) had its target price decreased by Royal Bank Of Canada from $233.00 to $213.00 in a research note published on Tuesday morning,MarketScreener reports. Royal Bank Of Canada currently has an outperform rating on the biotechnology company’s stock.

BIIB has been the subject of several other research reports. Piper Sandler lifted their price target on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Citigroup lifted their price target on Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Canaccord Genuity Group lifted their price target on Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. Finally, HC Wainwright lifted their price target on Biogen from $228.00 to $237.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Twelve equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $207.54.

Biogen Trading Up 1.9%

Shares of Biogen stock opened at $175.61 on Tuesday. The firm has a market cap of $25.77 billion, a price-to-earnings ratio of 19.93, a PEG ratio of 2.37 and a beta of 0.16. The business has a 50-day moving average price of $186.61 and a 200-day moving average price of $172.16. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts anticipate that Biogen will post 15.83 EPS for the current fiscal year.

Insider Activity

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BIIB. Reflection Asset Management purchased a new position in shares of Biogen during the fourth quarter valued at approximately $25,000. WPG Advisers LLC boosted its position in shares of Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the period. Accredited Wealth Management LLC boosted its position in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. First Horizon Corp purchased a new position in shares of Biogen during the fourth quarter valued at approximately $30,000. Finally, WFA of San Diego LLC bought a new stake in shares of Biogen during the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a multi‑target collaboration and license with Alloy Therapeutics to access its AntiClastic™ antisense platform—an expansion of Biogen’s RNA-targeting capabilities that can broaden its pipeline and long‑term revenue potential. Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
• Positive Sentiment: Analysts and screens note Biogen’s strong history of beating quarterly estimates and current drivers (pipeline momentum, Leqembi legacy revenue, and operating leverage) that make another earnings beat likely—supporting upside expectations. Why Biogen (BIIB) Could Beat Earnings Estimates Again
• Neutral Sentiment: RBC lowered its price target to $213 from $233 but kept an Outperform rating—this trims upside versus prior forecasts but leaves institutional support intact, which may stabilize sentiment longer term. RBC Capital Adjusts Biogen Price Target to $213 from $233, Maintains Outperform Rating
• Neutral Sentiment: Industry M&A activity and Biogen’s deal flow (reported interest/transactions in the sector and company-level deal talk) keep investors focused on strategic growth moves; such activity can be positive for long-term pipeline but uncertain for near-term cash/earnings. Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
• Negative Sentiment: Biogen disclosed that 1Q results will include an acquired in‑process R&D, upfront and milestone expense of roughly $34M (pre‑tax), a near‑term hit to reported profits. Biogen Expects 1Q Results Will Include Acquired In-Process R&D, Upfront and Milestone Expense of $34M on Pre-Tax Basis
• Negative Sentiment: Commentary flagged rising first‑quarter expenses that pressured the stock earlier in the week—this remains a near-term headwind that investors are weighing against pipeline and beat potential. Why Biogen Stock Got Mashed on Monday

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.